文献速递类风湿关节炎

基于网络的病人决策辅助工具对类风湿关节炎生物制剂和小分子药物的影响:概念验证研究结果

Effects of a Web-Based Patient Decision Aid on Biologic and Small-Molecule Agents for Rheumatoid Arthritis: Results From a Proof-of-Concept Study.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2018-02-06

该概念验证研究采用前后对照设计,纳入50例被推荐启用或更换生物制剂/小分子药物的类风湿关节炎患者,评估交互式在线决策辅助工具ANSWER-2的效果。使用后患者决策冲突量表得分平均下降21.2分(95%CI -28.1, -14.4),感知自我管理能力改善,但用药教育问卷仅自我管理子量表有统计学差异。

要点

  • ANSWER-2使用后决策冲突显著下降,DCS平均降低21.2分(P<0.001)。
  • PIHS评分平均降低3.7分(95%CI -6.3, -1.0,P=0.009),感知自我管理能力改善。
  • MeiQ结果混杂,仅自我管理子量表显示统计学显著差异。

核心结论

  • 使用ANSWER-2后患者决策冲突降低且感知自我管理能力改善,未来需与生物制剂教育材料比较以进一步明确其价值。

研究设计与样本

  • 前后对照的概念验证研究,纳入50例确诊类风湿关节炎且被推荐启用或更换生物制剂/小分子药物并有互联网接入的患者。

主要发现

  • 50例参与者多数为女性(n=40),平均年龄49.6±12.2岁,中位病程5年(25th,75th百分位:2,10年)。
  • DCS评分干预前45.9±25.1,干预后25.1±21.8,平均变化-21.2/100(95%CI -28.1, -14.4,P<0.001)。
  • 干预前20%参与者DCS评分<25,干预后为52%。
  • PIHS评分干预前25.3±14.8,干预后20.4±13.0,平均变化-3.7/88(95%CI -6.3, -1.0,P=0.009)。
  • MeiQ结果混杂,仅自我管理子量表显示统计学显著差异。

临床怎么用

  • 对于被推荐启用或更换生物制剂/小分子药物的类风湿关节炎患者,可考虑使用ANSWER-2在线决策辅助工具以降低决策冲突并改善感知自我管理能力。

局限性

  • 本研究为前后对照设计的概念验证研究,样本量50例,未来需与生物制剂教育材料比较以进一步验证其效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the extent to which ANSWER-2, an interactive online patient decision aid, reduces patients' decisional conflict and improves their medication-related knowledge and self-management capacity. METHODS: We used a pre-post study design. Eligible participants had a diagnosis of rheumatoid arthritis (RA), had been recommended to start using a biologic agent or small-molecule agent or to switch to a new one, and had internet access. Access to ANSWER-2 was provided immediately after enrollment. Outcome measures included 1) the Decisional Conflict Scale (DCS), 2) the Medication Education Impact Questionnaire (MeiQ), and 3) the Partners in Health Scale (PIHS). A paired t-test was used to assess differences pre- and postintervention. RESULTS: The majority of the 50 participants were women (n = 40), and the mean ± SD age of participants was 49.6 ± 12.2 years. The median disease duration was 5 years (25th, 75th percentile: 2, 10 years). The mean ± SD DCS score was 45.9 ± 25.1 preintervention and 25.1 ± 21.8 postintervention (mean change of -21.2 of 100 [95% confidence interval (95% CI) -28.1, -14.4], P < 0.001). Before using ANSWER-2, 20% of participants had a DCS score of <25, compared to 52% of participants after the intervention. Similar results were observed in the PIHS (mean ± SD 25.3 ± 14.8 preintervention and 20.4 ± 13.0 postintervention; mean change of -3.7 of 88 [95% CI -6.3, -1.0], P = 0.009). Findings from the MeiQ were mixed, with statistically significant differences found only in the self-management subscales. CONCLUSION: Patients' decisional conflict decreased and perceived self-management capacity improved after using ANSWER-2. Future research comparing the effectiveness of ANSWER-2 with that of educational material on biologic agents will provide further insight into its value in RA management.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Li LC, Shaw CD, Lacaille D, et al. Effects of a Web-Based Patient Decision Aid on Biologic and Small-Molecule Agents for Rheumatoid Arthritis: Results From a Proof-of-Concept Study. Arthritis Care Res (Hoboken). 2018. PMID: 28544648. doi:10.1002/acr.23287

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。